Breaking News

Kite announced the primary overall survival analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma within 12 months of completion of first-line therapy. Historical SOC is a multi-step process involving platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy and stem cell transplant in those who respond to salvage chemotherapy. These findings will be presented in full later this year at an upcoming scientific meeting. OS was designated as a clinically important prespecified key secondary endpoint, defined as the length of time from randomization to death from any cause. ZUMA-7 was conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration whereby the trial design, clinical endpoints and statistical analysis were agreed upon in advance with the Agency. This pre-specified analysis was also agreed by other health authorities. ZUMA-7 is considered a landmark trial as the first and largest Phase 3 study of any CAR T-cell therapy, with the longest follow-up, which has demonstrated event-free survival, the primary endpoint, that is superior to historical SOC treatment. Data from the ZUMA-7 pivotal trial led to the U.S. approval for initial treatment of R/R LBCL in April 2022 and European Union approval in October 2022, followed by approvals in a number of other countries such as: Great Britain, Israel, Japan, and Switzerland.

Gilead Sciences (GILD) and Nurix Therapeutics (NRIX) announced that Gilead has exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX-0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gilead collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation therapies. "Gilead's exercise of the first license option under our agreement is an important milestone and evidence of the significant progress that we have made in our strategic collaboration," said Gwenn Hansen, Ph.D., Chief Scientific Officer at Nurix. "Our highly productive DELigase platform has enabled us to advance multiple degrader programs in our collaboration with Gilead and across our wholly owned pipeline. This progress demonstrates the value of our research enterprise and its capacity to create medicines to address an array of therapeutic areas in addition to oncology." Under the terms of the parties' Collaboration, Option and License Agreement, for the NX-0479 option that Gilead is exercising, Nurix will receive an option exercise payment of $20 million and potentially could receive up to an additional $425 million in clinical, regulatory, and commercial milestone payments, as well as up to low double-digit tiered royalties on product net sales.

Gilead (GILD) and Nurix Therapeutics (NRIX) announced that Gilead has exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX-0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gilead collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation therapies. Under the terms of the parties' collaboration, option and license agreement, for the NX-0479 option that Gilead is exercising, Nurix will receive an option exercise payment of $20M and potentially could receive up to an additional $425M in clinical, regulatory, and commercial milestone payments, as well as up to low double-digit tiered royalties on product net sales.